Image source: Getty Images.
Since last summer, the market has distributed indiscriminate beatings across the biotechnology industry, and companies without approved products to sell have been hardest hit. The iShares Biotechnology ETF (NASDAQ: IBB), which tracks hundreds of biotech stocks, has rebounded from low points seen earlier this summer, but it’s still 25% lower than where it stood a year ago.